Johnson & Johnson: Overblown Stelara Concerns Distract From Value

BlackJack3DStelara, Johnson & Johnson's (NYSE:JNJ) leading product, is nearing the end of its exclusivity outside the US by mid-2024 and in the US by early 2025. Stelara is a significant part of JNJ's sales and operating income, making up about 13% of total sales and 24% of operating income in 2023. This loss of exclusivity will likely slow down the growth of earnings per share (EPS) for JNJ, which is a shift from their previous aim of growing EPS faster than sales. Analysts currently predict declines o ...